Degradable haemostat composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current haemostat compositions require removal after surgical procedures, increasing the risk of re-bleeding and complicating post-surgical recovery, as they are not designed to degrade safely within the body to aid in healing.
Innovation Solution
A fibrous chitosan salt or derivative composition, with a specific acid ratio and molecular weight, that degrades within 30 days, allowing it to remain in the body post-surgery to prevent re-bleeding and promote healing without the need for additional surgical removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional haemostat materials are used, then bleeding is controlled during surgery, but the materials must be removed after surgery which increases re-bleeding risk and complicates recovery
Solution Approach 1:
The patent modifies the chemical parameters of chitosan by controlling its molecular weight (50-500 kDa) and degree of deacetylation (75-85%), and by forming specific salts with physiologically acceptable acids. These parameter changes enable the material to degrade within 30 days while maintaining haemostatic properties, eliminating the need for surgical removal.
Solution Approach 2:
The invention creates a single-use, biodegradable haemostat that functions during surgery and then naturally degrades in the body within 30 days. This disposable approach eliminates the need for removal procedures, reducing re-bleeding risk and simplifying post-surgical care while maintaining effective haemostasis during the critical period.
2Duration of action of stationary object
If non-degradable haemostat materials are used, then haemostasis is maintained, but additional surgery is required for removal increasing patient complications
Solution Approach 1:
The chitosan salt composition is designed to self-degrade within the body through natural physiological processes. The material automatically breaks down into harmless byproducts within 30 days without requiring external intervention or surgical removal, thereby eliminating complications associated with removal procedures while maintaining haemostatic function during the critical healing period.
3Ease of manufacture
If rapidly degradable materials are used, then removal is unnecessary, but the material degrades too quickly to prevent post-surgical re-bleeding
Solution Approach 1:
The patent precisely controls the degradation rate by adjusting chitosan's molecular weight (50-500 kDa) and degree of deacetylation (75-85%), and by selecting specific physiologically acceptable acids for salt formation. These parameter optimizations ensure the material maintains structural integrity and haemostatic function for at least 30 days, providing sufficient protection against re-bleeding during the critical post-surgical period while ultimately degrading without surgical removal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively controls bleeding during and after surgery, reduces the risk of re-bleeding, and aids in the healing process by degrading naturally within the body, eliminating the need for post-operative removal and minimizing complications.
Implementation Method 1
Chitosan is converted to glucosamine by the enzyme lysozyme and is therefore excreted from the body naturally
Implementation Method 2
Chitosan is converted to glucosamine by the enzyme lysozyme
Data Source
AI summary
The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.